10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
Shares in Californian biotech MyoKardia slumped by 14% on Wednesday with the news that French pharma major Sanofi has pulled out of their collaboration in cardiovascular diseases. 3 January 2019
Chinese drug developer Connect Biopharmaceuticals has completed a $55 million Series B financing led by new investor Advantech Capital with participation by current investors Qiming Venture Partners, Northern Light Venture Capital, and Cowin Venture. CEC Capital acted as the exclusive financial advisor for the financing. 3 January 2019
Japanese conglomerate Itochu Corporation (TYO: 8001) has become the first lead investor in the Series D round of hepatology specialist Promethera Biosciences. 2 January 2019
Chinese biotech start-up Antengene Corp, a clinical stage therapeutics company focused on oncology, yesterday announced that it has completed a $120 million Series B financing. 2 January 2019
Patients with an advanced form of lung cancer will receive early access to Roche’s immunotherapy treatment Tecentriq (atezolizumab) in combination with chemotherapy and the Swiss company’s older oncology drug, Avastin (bevacizumab). 31 December 2018
Chinese regulator the National Medical Products Administration (NMPA) has approved Tyvyt (sintilimab) for the treatment of patients with classical Hodgkin's lymphoma (cHL) that has relapsed or refractory (r/r) after two or more lines of systemic chemotherapy (r/r cHL). 28 December 2018
BeiGene yesterday revealed that, on December 19, it received notice from Merck KGaA that the German firm was terminating for convenience the parties’ license agreement dated December 10, 2013, as amended, for the company’s investigational RAF dimer inhibitor lifirafenib (BGB-283) in the People’s Republic of China (PRC). 28 December 2018
Data from a planned interim analysis of the Phase III JAVELIN Ovarian 100 study of Bavencio (avelumab) did not support the study’s initial hypothesis, and therefore the developers made the decision to terminate the trial in alignment with the independent Data Monitoring Committee. 24 December 2018
US biotech Stemline Therapeutics has been granted US Food and Drug Administration approval of Elzonris (tagraxofusp-erzs; SL-401) for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients two years and older, in both treatment-naïve and previously-treated populations. 22 December 2018
Actelion Pharmaceuticals UK & Ireland, a subsidiary of US healthcare giant Johnson & Johnson today announced that National Health Service (NHS) patients in England, who have a rare and devastating disease, pulmonary arterial hypertension (PAH) can now be treated with Uptravi (selexipag). 22 December 2018
The US Food and Drug Administration today approved Ultomiris (ravulizumab) injection for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease. 21 December 2018
At a time when many big pharma companies are unreservedly buying into CAR-T therapies, Merck KGaA has taken a step away from the assets it has in the space. 21 December 2018
Not for the first time, US cost-effectiveness watchdog the Institute for Clinical and Economic Review’s (ICER) and the Institute for Patient Access (IfPA) are at loggerheads. 21 December 2018
China, with its reformed priority review and approval processes, is supporting biotech revolution in the country and thereby allowing domestic drug developers to compete with well-established multinational counterparts. 21 December 2018
US biotech firm Agenus leapt as much as 70% Thursday after announcing a deal with a biotech major, worth a potential $1.8 billion, and closed the day still up 23.38% at $2.48. 21 December 2018
Tokyo-based Chugai Pharmaceutical has won Japanese approval for additional dosing options for Hemlibra (emicizumab), a coagulation factor VIII substitute. 21 December 2018
The first quarter of 2019 will be an important one for Lundbeck as it moves on from the failure of its DAYBREAK trial of a schizophrenia drug with the launch of another medicine for the condition. 21 December 2018